These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32949267)

  • 1. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
    Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.
    Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
    Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
    Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
    Singh I; Patel R; Patel A; Jose V
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
    Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
    BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
    Hanes V; Chow V; Pan Z; Markus R
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
    Markus R; Chow V; Pan Z; Hanes V
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):755-763. PubMed ID: 28864922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
    Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
    Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
    Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
    Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
    Hummel M; Bosje T; Shaw A; Liu MS; Barve A; Kothekar M; Socinski MA; Waller CF
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):487-496. PubMed ID: 33866430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects.
    Zhu X; Ding Y; Yu Y; Wang M; Zhou W; Wang J; Zhu X; Zhang H; Wang M; Chai K; Zhang X; Luk A; Jiang W; Liu S; Zhang Q
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):349-359. PubMed ID: 33169186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
    Knight B; Rassam D; Liao S; Ewesuedo R
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study.
    Jeong H; Kang T; Lee J; Im S
    Int J Clin Pharmacol Ther; 2024 May; 62(5):231-240. PubMed ID: 38174886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.
    Liu YN; Huang J; Guo C; Yang S; Ye L; Wu ST; Zhang XF; Yang XY; Han CC; Pei Q; Huang L; He QN; Yang GP
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):555-562. PubMed ID: 31907645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
    Shin D; Lee Y; Kim H; Körnicke T; Fuhr R
    J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.
    Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
    Zhang H; Li Q; Zhu X; Li C; Li X; Liu C; Hu Y; Chen G; Wei H; Wang J; Shen Z; Ding Y
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):615-623. PubMed ID: 30043208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
    Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
    BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
    Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
    BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
    Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
    Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.